ICU Medical (NASDAQ:ICUI) Cut to Hold at Wall Street Zen

ICU Medical (NASDAQ:ICUI) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

A number of other research firms have also commented on ICUI. Piper Sandler upped their price target on shares of ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a report on Friday, November 7th. KeyCorp raised their target price on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $175.67.

ICU Medical Stock Performance

NASDAQ ICUI opened at $154.16 on Friday. The firm has a market cap of $3.81 billion, a price-to-earnings ratio of -497.27 and a beta of 0.79. The company has a 50-day simple moving average of $148.59 and a two-hundred day simple moving average of $134.41. The company has a quick ratio of 1.19, a current ratio of 2.45 and a debt-to-equity ratio of 0.62. ICU Medical has a 12-month low of $107.00 and a 12-month high of $165.17.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.60. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.The business had revenue of $533.30 million for the quarter, compared to analyst estimates of $511.46 million. During the same period last year, the company earned $1.59 EPS. ICU Medical’s revenue for the quarter was down 8.9% compared to the same quarter last year. On average, equities analysts forecast that ICU Medical will post 4.11 EPS for the current year.

Insider Buying and Selling

In other news, Director Elisha W. Finney sold 1,285 shares of the company’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total value of $180,439.70. Following the sale, the director directly owned 3,995 shares of the company’s stock, valued at $560,977.90. This represents a 24.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Virginia Ruth Sanzone sold 930 shares of the stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total transaction of $132,376.20. Following the completion of the transaction, the vice president owned 5,456 shares of the company’s stock, valued at approximately $776,607.04. The trade was a 14.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

A number of institutional investors and hedge funds have recently made changes to their positions in ICUI. Cullen Frost Bankers Inc. bought a new stake in shares of ICU Medical in the 2nd quarter worth approximately $38,000. SJS Investment Consulting Inc. raised its stake in ICU Medical by 41,000.0% during the third quarter. SJS Investment Consulting Inc. now owns 411 shares of the medical instruments supplier’s stock valued at $49,000 after buying an additional 410 shares during the last quarter. Covestor Ltd boosted its holdings in ICU Medical by 70.7% in the third quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 236 shares in the last quarter. Strs Ohio grew its stake in shares of ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after acquiring an additional 300 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in shares of ICU Medical by 17.6% during the second quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock valued at $124,000 after acquiring an additional 141 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.